Sonnet BioTherapeutics Holdings, Inc. Appoints Stephen J. McAndrew as Chief Business Officer
PRINCETON, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) —
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the “Company” or “Sonnet”), a clinical-stage company developing targeted immunotherapeutic drugs, announced today the appointment of Stephen J. McAndrew, Ph.D., as Chief Business Officer, effective February 17, 2025.
Sonnet BioTherapeutics Holdings, Inc. has made a significant leadership change with the appointment of Stephen J. McAndrew, Ph.D., as the new Chief Business Officer. This move comes as the Company continues to focus on its mission of developing targeted immunotherapeutic drugs to address unmet medical needs.
Dr. McAndrew brings a wealth of experience and expertise to his new role at Sonnet BioTherapeutics. With a background in business development and a deep understanding of the biopharmaceutical industry, he is well-equipped to drive strategic partnerships and collaborations for the Company.
As Chief Business Officer, Dr. McAndrew will play a key role in leading Sonnet BioTherapeutics towards its goal of developing innovative therapies that have the potential to transform the treatment landscape for patients battling various diseases.
This appointment underscores Sonnet BioTherapeutics’ commitment to advancing its pipeline of immunotherapies and bringing novel treatment options to patients in need. Dr. McAndrew’s leadership will undoubtedly contribute to the Company’s growth and success in the coming years.
How This Appointment Will Affect Me
As a consumer, the appointment of Stephen J. McAndrew as Chief Business Officer at Sonnet BioTherapeutics may impact me indirectly. If the Company’s research and development efforts under his leadership lead to the development of new immunotherapeutic drugs, there is a possibility that innovative treatment options could become available for patients in the future.
How This Appointment Will Affect the World
The appointment of Dr. McAndrew as Chief Business Officer at Sonnet BioTherapeutics has the potential to have a broader impact on the world. By driving strategic partnerships and collaborations in the biopharmaceutical industry, he may contribute to advancing scientific knowledge and developing new therapies that could benefit patients globally.
Conclusion
The appointment of Stephen J. McAndrew, Ph.D., as Chief Business Officer at Sonnet BioTherapeutics Holdings, Inc. marks an important milestone for the Company as it continues on its mission to develop targeted immunotherapeutic drugs. Dr. McAndrew’s expertise and leadership will be instrumental in driving strategic growth and innovation, ultimately benefiting patients and the broader healthcare community.
